Base editing approaches to treat SCD aim to increase the expression of HbF by editing transcriptional repressor BCL11A, or BCL11A binding regions HBG1 and HBG2, as well as editing binding sites of transcriptional activators of γ-globin genes [38]. The gene discussed is BCL11A; the disease is Schnyder corneal dystrophy.